State Street Corp Sage Therapeutics, Inc. Call Options Transaction History
State Street Corp
- $2.8 Trillion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SAGE
# of Institutions
77Shares Held
17.5MCall Options Held
282KPut Options Held
320K-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V8599KShares$5.2 Million0.03% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ582KShares$5.05 Million0.02% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL143KShares$1.24 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V8103KShares$897,5640.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...